Volpara Health Technologies Limited

Volpara Solutions is committed to helping save families from cancer (ASX: VHT). Volpara’s advanced technology platform combines with the healthcare provider’s expertise to provide a high-quality, optimized and personalized cancer screening experience. From the time a patient enters a clinic to when they obtain key results, our platform collects and analyzes information to better understand a patient’s breast cancer risk, while also objectively evaluating image quality and workflow opportunities. These capabilities are being extended to lung cancer screening.

Volpara’s platform is supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking, and validated by a volume of peer-reviewed publications unrivalled in the breast screening industry.

ASX Code
VHT

Sector
Health Care Equipment & Services

Website
https://volparasolutions.com/

Spotlight Videos

Next generation breast cancer screening

May 31, 2021 - by Company News

Presenter - Ralph Highnam - CEO - Volpara Health provides clinically validated, AI-powered software for personalized screening and early detection of breast cancer.

Watch Now

Volpara Health Technologies (ASX: VHT) – Hidden Gems Webinar Presentation

October 13, 2020 - by Company News

Presenter – Ralph Highnam - CEO - Volpara is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. Volpara's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice software management helps with productivity, compliance, reimbursement, and patient tracking.

Watch Now

News

What to know about the TechKnow Invest Roadshow

July 26, 2023 - by Peter Milios

Whilst the prevalence of Artificial intelligence has boosted the US tech sector, Australian tech stock valuations have largely been dampened amid rising interest rates, macroeconomic uncertainties and geopolitical tensions.

VHT – Morgans rates the stock as Add

January 20, 2022 - by Broker News

The broker adopts a changed valuation method and raises its target price to $1.94 from $1.87. Add retained.

VHT – Morgans rates the stock as Add

October 27, 2021 - by Broker News

Morgans makes no changes to forecasts and retains its Add rating and $1.87 target price after Volpara Health Technologies reported a "solid" 2Q result.

VHT – Morgans rates the stock as Add

March 19, 2021 - by Broker News

Via the recent CRA Health acquistion, Volpara Health Technologies has announced its largest contract to date worth over US$400,000 per annum. The Add rating is maintained and the target price is increased to $1.94 from $1.92.

VHT – Morgans rates the stock as Add

February 3, 2021 - by Broker News

Volpara Health Technologies has completed a strategic acquisition of CRA Health, a Boston based breast cancer risk assessment company. Morgans' add rating is maintained and the target price is increased to $1.92 from $1.70.

VHT – Morgans rates the stock as Add

January 29, 2021 - by Broker News

Volpara Health Technologies posted a third quarter cashflow report in-line with the expectations of Morgans. The add rating is maintained and the target price is decreased to $1.70 from $1.71.

VHT – Morgans rates the stock as Add

December 23, 2020 - by Broker News

Volpara Health Technologies has signed a five-year SaaS contract with BreastScreen Queensland for the quality assurance platform, VolparaEnterprise. Morgans makes no changes to forecasts, and the Add rating and target price of $1.71 are unchanged.

2020 Picks Of The Year: But How Did 2019 Pick’s Go?

December 19, 2019 - by Greg Tolpigin

It’s that time of the year again where predictions are made for 2020 and before embarking on those, I always think it is worth reviewing last year’s key ideas

Volpara Acquisition Accelerates Future Growth

June 7, 2019 - by Greg Tolpigin

Volpara Health (VHT) has been a stock that I have highlighted a couple of times, including at the start of the year where it was one of the few companies that was attractive according to my strict stock selection process. This week the company raised $55 million to acquire MRS Systems in the United States and accelerate their sales team and market penetration.

Volpara Health: Becoming The Industry Standard

April 1, 2019 - by Greg Tolpigin

VHT is right up there with my favourite stocks not just for 2019 but for years to come as it is one of the few times where I can truly say I have confidence in their business, their product and the industry – a change from an alternative to the standard.